Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Genie29jon Nov 07, 2020 8:13am
70 Views
Post# 31857097

RE:RE:RE:RE:RE:Replicel Twitter

RE:RE:RE:RE:RE:Replicel Twitter

Right, YOFOTO has everything other than RCH-01. So my guess with that is YOFOTO finally has the green light to begin phase two of the studies for skin and/or tendon

In my personal opinion I think it's the tendon technology that will be the greatest success. For two reasons.
1. It had some of the best phase 1 results 
2. If it works really well, this would not be considered a cosmetic procedure, unlike skin and hair, so therefore, they could charge a very high amount because it would most likely be covered through a health insurance plan. That could be huge! 


get excited boys & girls! I think the next 18 months will be much more fun than the previous 18+ 

<< Previous
Bullboard Posts
Next >>